Skip to main content

Advertisement

SpringerLink
Log in

Hepatitis C Direct-Acting Antiviral Agents in HIV/HCV Co-infected Patients

  • HIV Medicine (CJ Yoon, Section Editor)
  • Published:
Current Treatment Options in Infectious Diseases Aims and scope Submit manuscript

Opinion statement

At the time this article is being written, hepatitis C treatment is being revolutionized. The recent approval of sofosbuvir in the US for both mono- and co-infection is an astounding advance in the treatment for co-infection. In the label, there is no distinction between the treatment of co-infected and mono-infected patients. This has been shown to be true of all the direct-acting antiviral agents to date, but none so far have had it in their label. In our opinion, patients in the early stages of liver fibrosis can wait for the future combinations of agents to optimize their treatment responses and limit the risks of adverse events. For those who cannot wait, clinicians should follow the guidelines for mono-infected patients after the management of potential drug-drug interactions between the patient’s antiretroviral agents and hepatitis C direct-acting antiviral agents. A combination of pegylated-interferon and ribavirin with telaprevir, boceprevir, simeprevir, or sofosbuvir is adequate for genotype 1. For genotype 2, 12 weeks of sofosbuvir and ribavirin is recommended, and for genotype 3, 24 weeks of sofosbuvir and ribavirin are the label recommendations. For genotypes 4, 5, and 6, pegylated-interferon, ribavirin, and sofosbuvir is preferred. There is also an option for interferon-ineligible patients to use 24 weeks of sofosbuvir and ribavirin and to use up to 365 days of sosfosbuvir in patients with hepatocellular carcinoma awaiting liver transplant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance; •• Of major importance

  1. Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007;21(16):2209–16.

    Article  PubMed  Google Scholar 

  2. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18(13):F27–36.

    Article  CAS  PubMed  Google Scholar 

  3. Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007;23(8):972–82.

    Article  CAS  PubMed  Google Scholar 

  4. Moreno A, Quereda C, Moreno L, Perez-Elias MJ, Muriel A, Casado JL, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther. 2004;9(1):133–8.

    CAS  PubMed  Google Scholar 

  5. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 2006;13(10):683–9.

    Article  CAS  PubMed  Google Scholar 

  6. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–16.

    Article  CAS  PubMed  Google Scholar 

  7. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014–24.

    Article  CAS  PubMed  Google Scholar 

  8. Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Vachon ML, Factor SH, Branch AD, Fiel MI, Rodriguez-Torres M, Brau N, et al. Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-alpha-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol. 2011;54(1):41–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Mandorfer M, Reiberger T, Payer BA, Ferlitsch A, Breitenecker F, Aichelburg MC, et al. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients. AIDS. 2013;27(2):227–32.

    Article  CAS  PubMed  Google Scholar 

  11. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50(2):407–13.

    Article  CAS  PubMed  Google Scholar 

  12. Mira JA, Rivero-Juarez A, Lopez-Cortes LF, Giron-Gonzalez JA, Tellez F, de los Santos-Gil I, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013;56(11):1646–53.

    Article  CAS  PubMed  Google Scholar 

  13. INCIVEKTM (telaprevir) Film Coated Tablets, for oral use Revised: 10/13 [December 1, 2013]. Available from: http://pi.vrtx.com/files/uspi_telaprevir.pdf.

  14. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59(3):434–41. This is a major real-life study for boceprevir and telaprevir.

    Article  PubMed  Google Scholar 

  15. Heeswijk Rv, Vandevoorde A, Boogaerts G, Vangeneugden T, Paepe Ed, Polo R., et al. Pharmacokinetic Interactions between ARV Agents and the Investigational HCV Protease Inhibitor TVR in Healthy Volunteers. 18th Conference on Retroviruses and Opportunistic Infections (CROI). 2011;Abstract 119(Boston (USA)).

  16. Heeswijk Rv, Garg V, Boogaerts G, Vandebosch A, Luo D, Witek J., et al. The Pharmacokinetic Interaction Between Telaprevir & Raltegravir in Healthy Volunteers 51st ICAAC. 2011;Abstract A1–1738a(Chicago (USA)).

  17. Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol. 2013;75(2):431–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86–96. This is the first telaprevir study for co-infected patients.

    PubMed  Google Scholar 

  19. Campos NG, Salomon JA, Servoss JC, Nunes DP, Samet JH, Freedberg KA, et al. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med. 2007;120(3):272–9.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Hornberger J, Torriani FJ, Dieterich DT, Brau N, Sulkowski MS, Torres MR, et al. Cost-effectiveness of peginterferon alfa-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol: Official Publication of the Pan American Society for Clinical Virology. 2006;36(4):283–91.

    Article  CAS  Google Scholar 

  21. Camma C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, et al. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J Hepatol. 2013;59(4):658–66.

    Article  PubMed  Google Scholar 

  22. Camma C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2012;56(3):850–60.

    Article  PubMed  Google Scholar 

  23. Victrelis (boceprevir) Capsules for oral use: Full prescribing information Revised: 9/2013 [December 8, 2013]. Available from: http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf.

  24. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13(7):597–605. This is the first boceprevir study for co-infected patients.

    Article  CAS  PubMed  Google Scholar 

  25. Antiviral Drugs Advisory Committee Meeting - Briefing Document - Simeprevir (TMC435) Treatment of Patients with Chronic Hepatitis C - NDA 205123 2013 [cited 2013 December 1, 2013]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM371624.pdf.

  26. Dieterich D, Rockstroh J, Orkin C, Gutiérrez F, Klein MB, Reynes J, et al. Simeprevir (TMC435) in combination with peginterferon/ribavirin in patients co-infected with HCV genotype-1 and HIV-1: primary analysis of the C212 study 14th European AIDS Conference Brussels, Belgium 2013. This is the first simeprevir study for co-infected patients.

  27. Sulkowski MS, Rodriguez-Torres M, Lalezari JP, Fessel WJ, Mounzer K, Shuhart MC, et al. All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1). Hepatology. 2013;58(S1):313–4A. This is the first sofosbuvir study for co-infected patients.

    Article  Google Scholar 

  28. Gilead. U.S. Food and Drug Administration Approves Gilead’s Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C - See more at: http://www.gilead.com/news/press-releases/2013/12/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c-sthash.1QucuMOJ.dpuf 2013 [cited 2013 December 8, 2013]. Available from: http://www.gilead.com/news/press-releases/2013/12/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c.

  29. Food and Drug Administration Center for Drug Evaluation - Research Office of Antimicrobial Products - Division of Antiviral Products .FDA Antiviral Drug Advisory Committee Meeting - October 25, 2013 - Background Package for NDA 204671 Sofosbuvir (GS-7977) 2013 [cited 2013 December 1, 2013]. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/antiviraldrugsadvisorycommittee/ucm371876.pdf.

  30. Rockstroh J, Nelson M, Soriano V, Arastéh K, Guardiola J, Bhagani S, et al. STARTVerso4 phase III trial of faldaprevir plus pegylated interferon α-2a and ribavirin in patients with HIV and HCV genotype-1 co-infection. Hepatology. 2013;58(S1):741A. This is the first faldaprevir study for co-infected patients.

    Google Scholar 

  31. Bifano M, Hwang C, Oosterhuis B, Hartstra J, Tiessen R, Velinova-Donga M., et al. Assessment of HIV ARV Drug Interactions with the HCV NS5A Replication Complex Inhibitor BMS-790052 Demonstrates a Pharmacokinetic Profile which Supports Co-administration with Tenofovir Disoproxil Fumarate, Efavirenz, and Atazanavir/ritonavir. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA. 2012.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Valérie Martel-Laferrière reports no conflicts of interest.

Douglas T. Dieterich is a paid consultant for Gilead, Bristol-Myer-Squibb, Merck, Idenix, Boehringer Ingelheim, and Janssen.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.

Author information

Authors and Affiliations

  1. Département de Microbiologie et Infectiologie, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada

    Valérie Martel-Laferrière MD

  2. Department of Medicine, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Douglas T. Dieterich MD

  3. One Gustave L. Levy Place, New York, NY, 10029, USA

    Douglas T. Dieterich MD

Authors
  1. Valérie Martel-Laferrière MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Douglas T. Dieterich MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas T. Dieterich MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martel-Laferrière, V., Dieterich, D.T. Hepatitis C Direct-Acting Antiviral Agents in HIV/HCV Co-infected Patients. Curr Treat Options Infect Dis 6, 132–143 (2014). https://doi.org/10.1007/s40506-014-0010-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40506-014-0010-8

Keywords

Search

Navigation